Citi analyst, Liav Abraham, reiterated his Buy rating on shares of Insmed (NASDAQ: INSM) and raised his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE